United Therapeutics (NASDAQ:UTHR) Hits New 1-Year High - What's Next?

Key Points

• United Therapeutics' stock price reached a new 52-week high of $437.95 during mid-day trading, closing at $435.51.
• Numerous analysts have raised their target prices for United Therapeutics, with a consensus rating of "Moderate Buy" and a target of $438.85.
• The company reported earnings of $6.41 per share, missing estimates, with a revenue of $798.60 million, reflecting an 11.7% year-over-year increase.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $437.95 and last traded at $435.51, with a volume of 829578 shares traded. The stock had previously closed at $414.73.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Jefferies Financial Group raised their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a report on Thursday, September 4th. HC Wainwright raised their price target on United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research report on Friday, September 5th. Morgan Stanley cut their target price on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. Finally, Oppenheimer upped their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research report on Friday, September 5th. Nine equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $438.85.

United Therapeutics Stock Performance

The business has a fifty day simple moving average of $331.90 and a 200-day simple moving average of $311.38. The stock has a market capitalization of $19.58 billion, a P/E ratio of 16.94, a PEG ratio of 6.37 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm's revenue was up 11.7% compared to the same quarter last year. During the same period in the prior year, the company earned $5.85 earnings per share. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the transaction, the executive vice president owned 36,781 shares in the company, valued at $11,356,133.75. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 176,435 shares of company stock worth $65,503,807. Corporate insiders own 10.30% of the company's stock.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC bought a new position in shares of United Therapeutics in the second quarter valued at approximately $29,000. SVB Wealth LLC purchased a new position in shares of United Therapeutics in the 1st quarter worth about $32,000. WealthCollab LLC grew its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. grew its position in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 46 shares during the period. Finally, Geneos Wealth Management Inc. increased its holdings in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after buying an additional 85 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.